Skip to main content

Table 2 Univariate and multivariate analysis for relapse, DFS, and OS

From: Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

Variable

Relapse

DFS

OS

Univariate

Multivariate (HR)

Univariate

Multivariate (HR)

Univariate

Multivariate (HR)

Donortype

HID vs MSD

P= .034

P= .047 (0.615)

95%CI 0.381–0.994

P= .665

–

P= .832

–

Male/female

P= .362

–

P= .680

–

P= .433

–

Patient age, ≥ 28 years old vs < 28 years old

P= .183

–

P= .219

–

P= .376

–

AML/non-AML

P= .204

–

P= .518

–

P= .448

–

Genetics:poor-risk vs others

P= .321

–

P= .254

–

P= .489

–

Disease stage at transplants:relapse refractory vs PIF

P= .048

P= .121 (1.449)

95%CI 0.907–2.314

P= .084

P= .148 (1.288)

95%CI 0.914–1.815

P= .131

–

WBC count at diagnosis:high vs others

P= .659

–

P= .343

–

P= .247

–

BM blasts before conditioning, ≥ 32% vs < 32% (median)

P= .191

–

P= .206

–

P= .245

–

BM blasts on day 0, ≥ 3% vs < 3% (median)

P= .004

P= .037 (1.652)

95%CI 1.032-2.640

P< .001

P= .005 (1.630)

95%CI 1.162-2.288

P= .001

P= .011 (1.573)

95%CI 1.110-2.229

MRD status post-transplant, pos vs neg

P= .002

P = .003 (2.019)

95%CI 1.267–3.216

P= .005

P= .003 (1.668)

95%CI 1.185–2.347

P= .019

P= .027 (1.490)

95%CI 1.048–2.121

DLI vs no DLI

P= .025

P= .034 (0.561)

95%CI 0.329–0.957

P< .001

P< .001 (0.402)

95%CI 0.275–0.588

P< .001

P< .001 (0.423)

95%CI 0.289–0.620

II-IV aGVHD vs 0-I aGVHD

P= .212

–

P= .530

–

P= .558

–

cGVHD vs no cGVHD

P= .003

P= .023 (0.580)

95%CI 0.363–0.928

P= .003

P= .016 (0.659)

95%CI 0.470–0.925

P= .050

P= .108 (0.788)

95%CI 0.557–1.116

  1. HID haploidentical related donor, MSD matched sibling donor, AML acute myelogenous leukemia, non-AML acute leukemia other than AML, OS overall survival, DFS disease free survival, PIF primary induction failure, BM bone marrow, high WBC count at diagnosis WBC count ≥ 30,000 per mm3, MRD minimal residual disease